España
India
Italia
대한민êµ
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민êµ
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Amicus Therapeutics
FOLD
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$9.80
0.00
0.00%
Pre-Market: Dec 20, 4:37 PM EDT
Get Report
Comment
Amicus Therapeutics (FOLD) Forecast
News
Earnings
Amicus Therapeutics (FOLD) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Government Trades
Short Interest
Latest news for Amicus Therapeutics (NASDAQ:FOLD) Stock
Amicus Therapeutics Stock (NASDAQ: FOLD)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, December 13, 2024
Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?
Vandana Singh
Morgan Stanley Downgrades Amicus Therapeutics...
Benzinga Newsdesk
Tuesday, November 12, 2024
A Closer Look at 8 Analyst Recommendations For Amicus Therapeutics
Benzinga Insights
The Analyst Verdict: Amicus Therapeutics In The Eyes Of 8 Experts
Benzinga Insights
Amicus Therapeutics Stock: A Deep Dive Into Analyst Perspectives (8 Ratings)
Benzinga Insights
JP Morgan Maintains Overweight on Amicus Ther...
Benzinga Newsdesk
Thursday, November 07, 2024
Guggenheim Maintains Buy on Amicus Therapeuti...
Benzinga Newsdesk
Cantor Fitzgerald Maintains Overweight on Ami...
Benzinga Newsdesk
Peeling Back The Layers: Exploring Amicus Therapeutics Through Analyst Insights
Benzinga Insights
Needham Reiterates Hold on Amicus Therapeutic...
Benzinga Newsdesk
Wednesday, November 06, 2024
Amicus Therapeutics shares are trading higher...
Benzinga Newsdesk
Amicus Therapeutics Raises 2024 Total Revenue...
Benzinga Newsdesk
Amicus Therapeutics Q3 2024 Adj EPS $0.10 Up ...
Benzinga Newsdesk
Thursday, October 17, 2024
Alnylam Stock Up on Cardiomyopathy Drug Regulatory Filing in the EU
Zacks
B of A Securities Maintains Buy on Amicus The...
Benzinga Newsdesk
Amicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder Drug
Vandana Singh
Travelers Posts Upbeat Results, Joins Iridium Communications, Snap-on And Other Big Stocks Moving Higher On Thursday
Avi Kapoor
Amicus Therapeutics shares are trading higher...
Benzinga Newsdesk
Amicus Therapeutics Enters License Agreement ...
Benzinga Newsdesk
Wednesday, October 16, 2024
MGTX Stock Up on Upbeat Efficacy Data From Parkinson's Disease Study
Zacks
Friday, October 11, 2024
Expert Outlook: Amicus Therapeutics Through The Eyes Of 4 Analysts
Benzinga Insights
Morgan Stanley Maintains Overweight on Amicus...
Benzinga Newsdesk
Friday, September 20, 2024
Cantor Fitzgerald Reiterates Overweight on Am...
Benzinga Newsdesk
Friday, September 06, 2024
Jefferies Initiates Coverage On Amicus Therap...
Benzinga Newsdesk
Friday, August 16, 2024
JP Morgan Maintains Overweight on Amicus Ther...
Benzinga Newsdesk
Friday, August 09, 2024
Needham Reiterates Hold on Amicus Therapeutic...
Benzinga Newsdesk
Thursday, August 08, 2024
Amicus Therapeutics shares are trading higher...
Benzinga Newsdesk
Amicus Therapeutics Raises FY24 Sales Outlook...
Benzinga Newsdesk
Amicus Therapeutics Q2 2024 Adj. EPS $0.06 Be...
Benzinga Newsdesk
Thursday, May 30, 2024
Wells Fargo Initiates Coverage On Amicus Ther...
Benzinga Newsdesk
Tuesday, May 14, 2024
Evaluating Amicus Therapeutics: Insights From 6 Financial Analysts
Benzinga Insights
This Boston Beer Analyst Turns Bullish; Here Are Top 5 Upgrades For Today.
Avi Kapoor
Amicus Therapeutics shares are trading higher...
Benzinga Newsdesk
Guggenheim Upgrades Amicus Therapeutics to Bu...
Benzinga Newsdesk
Friday, May 10, 2024
UBS Maintains Buy on Amicus Therapeutics, Low...
Benzinga Newsdesk
Morgan Stanley Maintains Overweight on Amicus...
Benzinga Newsdesk
B of A Securities Maintains Buy on Amicus The...
Benzinga Newsdesk
Needham Reiterates Hold on Amicus Therapeutic...
Benzinga Newsdesk
Thursday, May 09, 2024
Amicus Therapeutics shares are trading lower ...
Benzinga Newsdesk
Amicus Forecasts 2024 Total Revenue Growth Of...
Benzinga Newsdesk
Amicus Therapeutics Q1 2024 Adj EPS $(0.02) B...
Benzinga Newsdesk
Monday, March 18, 2024
JP Morgan Maintains Overweight on Amicus Ther...
Benzinga Newsdesk
Thursday, February 29, 2024
Cantor Fitzgerald Reiterates Overweight on Am...
Benzinga Newsdesk
Wednesday, February 28, 2024
Amicus Therapeutics Projects 2024 Galafold Re...
Benzinga Newsdesk
Amicus Therapeutics Q4 Adj EPS $0.01 Beats $(...
Benzinga Newsdesk
Earnings Scheduled For February 28, 2024
Benzinga Insights
Thursday, February 08, 2024
Amicus Therapeutics Says It Received 2024 New...
Benzinga Newsdesk
Sunday, January 07, 2024
Amicus Therapeutics Reports Preliminary 2023 ...
Benzinga Newsdesk
Tuesday, December 19, 2023
The Analyst Landscape: 4 Takes On Amicus Therapeutics
Benzinga Insights
Morgan Stanley Upgrades Amicus Therapeutics t...
Benzinga Newsdesk
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch